Alvotech (OISE:ALVO) Moat Score: 5/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OISE:ALVO Alvotech OISE:ALVO
55 GF Score
Price kr409.00
GF Value kr2,307.75
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Alvotech Moat Score?

Alvotech OISE:ALVO -1.21% 55 Moat Score is 5 as of Jul. 15, 2026. GuruFocus rates OISE:ALVO with a GF Score™ of 55/100 and a GF Value™ of kr2,307.75 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Alvotech ranks better than 94.67% on this metric.

Alvotech has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Alvotech has Narrow Moat: Alvotech has a solid narrow moat due to its focus on biosimilars, which provides some market differentiation. The company benefits from valuable intellectual property and R&D capabilities, but lacks the scale and pricing power to achieve a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Alvotech might have Narrow Moat - Solid narrow moat.

Alvotech  (OISE:ALVO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Alvotech Moat Score Related Terms

OISE:ALVO vs PAHC, COLL, XERS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alvotech Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alvotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Alvotech's Moat Score falls into.


OISE:ALVO
55GF Score
Alvotech OISE:ALVO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Alvotech (OISE:ALVO) has a Moat Score of 5 as of Jul. 15, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Alvotech ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Alvotech's Moat Score too high?
Alvotech's current Moat Score is 5. Based on the distribution chart, Alvotech ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alvotech has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Moat Score compare to PAHC and COLL?
According to the Drug Manufacturers industry distribution chart, Alvotech ranks #55 out of 1031 companies for Moat Score. This places Alvotech in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Alvotech's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,307.75, compared to a current price of kr409.00 — trading 82.3% below its estimated fair value. The current Moat Score is 5. Alvotech's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current Moat Score is 5 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (OISE:ALVO) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of kr409.00 is trading 82.3% below its estimated GF Value™ of kr2,307.75. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for OISE:ALVO:

  • Moat Score: 5
  • GF Value™: kr2,307.75 vs. price of kr409.00 (82.3% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alvotech Business Description

Other Exchanges ALVO:USAZ45:Germany
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
55GF Score

Get the complete analysis for OISE:ALVO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr409.00
Price
kr2,307.75
GF Value